Next 10 |
home / stock / nktx / nktx articles
Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeti...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 whil...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE: ABBV) an...
Over the past twenty days of trading, Nkarta Inc. (NASDAQ: NKTX), from February 23, 2024 to March 21, 2024 there is a potential Short Squeeze abou...
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adj...
Thursday, in its fourth quarter 2023 earnings release, Nkarta Inc (NASDAQ:NKTX) said it closed patient enrollment in its clinical trial o...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Nkarta, Inc. (NASDAQ: NKTX) posted a loss for the fourth quarter on Thursday. The company posted a quarterly loss of 57 cents per share, compared ...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered nat...
News, Short Squeeze, Breakout and More Instantly...
Nkarta Inc. Company Name:
NKTX Stock Symbol:
NASDAQ Market:
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments Strong balance sheet, bolstered by recent $240.1 milli...
Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeti...